Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 15;9(11):eade6675. doi: 10.1126/sciadv.ade6675

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).

This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 4. — (A and B) Pharmacokinetic analysis of the drug pyrimethamine in study participants from pyrimethamine (blue) and the combination treatment arm with pyrimethamine and VPA (green) as measured by median total pyrimethamine (mg/liter) levels in plasma with IQRs at 6 hours after first dosing (day 0, t = 6 hours), at the end of treatment period (day 14), and 28 days after the end of treatment (day 42) overall (A) and in those with uninterrupted pyrimethamine exposure (B) and represented as plasma pyrimethamine levels at the time points per individual on pyrimethamine (C) or the combination treatment with pyrimethamine and VPA (D).